Abdulrahman Nasiri։ Decade of Evidence Supports ASCT2 in Relapsed Multiple Myeloma
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared Mostafa Faisal Mohammed Saleh’s post on LinkedIn, adding:
”Honored to contribute to this review published in Current Oncology MDPI, evaluating a decade of evidence on second or salvage autologous stem cell transplantation in relapsed multiple myeloma.
This work reinforces that ASCT2 remains a clinically meaningful, risk-adapted option for selected patients, particularly those with prolonged first remission and chemosensitive relapse, even in the era of CAR-T and bispecific antibodies.
Grateful to collaborate with distinguished colleagues Marwa Nassar, Nourah Alzaidy, Amr Hanbali, Mahmoud Aljurf, and Mostafa Faisal Mohammed Saleh.
It was a privilege to work together on this important analysis.”
Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our recent review just out in Current Oncology: ASCT2 in relapsed MM (2016 – 2026) across14 key studies.
Feasible and safe: NRM 1–4% (day 100–1y) across large registries (n=305–975).
Median PFS 9.8–30.2 mo; OS ~30 to >80 mo depending on risk.
Interval ≥24 mo from ASCT1 = strongest predictor → PFS 17–45 mo; OS >60–80 mo in favorable subsets.
Maintenance matters: lenalidomide PFS 41 vs 21.6 mo; carfilzomib-dex TTP 25.1 vs 16.7 mo.
Phase III GMMG ReLApsE: no PFS/OS superiority (20.5 vs 19.3 mo; OS 67.1 vs 62.7) → selection is key.
In the CAR-T/bispecific era, ASCT2 = risk-adapted consolidation or bridge — not routine salvage.”
Title: Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016–2026): A Decade in Review
Authors: Marwa Nassar, Nourah Alzaidy, Abdulrahman Nasiri, Amr Hanbali, Mahmoud A. Aljurf, Mostafa F. Mohammed Saleh
Read the Full Article on Current Oncology․
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 18, 2026, 15:01A. M. Thirugnanam: Antiplatelet Discontinuation and the Risk of Stent Thrombosis
-
Sep 18, 2026, 14:52Abdul Muqtadir Abbasi: How Do Hematologists Know Which Coagulation Factor Is the Problem?
-
Sep 18, 2026, 14:48Kato Ramaekers: Redefining Integrin αIIbβ3 in Platelet Formation
-
Sep 18, 2026, 14:33Heghine Khachatryan: The discussion of Thrombophilia, APS and Coagulation Testing
-
Sep 18, 2026, 14:27Maria Cherska: Are We Overlooking the Spleen in Cardiometabolic Research?
-
Sep 18, 2026, 14:05Wolfram Ruf: Managing Thrombotic Risk in Pregnancy
-
Sep 18, 2026, 13:38Sam Tsimikas: Uncovering a Modifiable Lp(a) Phenotype in Hypertriglyceridemia
-
Sep 18, 2026, 13:22Christine Rabinak: Predictive Modeling for Individualized Unfractionated Heparin Dosing
-
Sep 18, 2026, 13:07Bastu Odoka: Principles of Pediatric Transfusion Dosing